Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Inclusion Criteria: * Must be American Society of Anesthesiologists (ASA) Class 1, 2, or 3 * Must be scheduled for a hip fracture surgery or joint (hip or knee) replacement surgery under general anesthesia including the use of rocuronium or vecuronium for neuromuscular blockade * Must be: * Currently receiving thromboprophylactic (anti-clotting) therapy with low molecular weight heparin (LMWH) or unfractionated heparin (UFH), or * Planned to initiate thromboprophylactic therapy with LMWH or UFH prior to or during surgery, or * Currently receiving ongoing thromboprophylactic therapy with a vitamin K antagonist that has been temporarily substituted with peri-operative LMWH or UFH, and/or * Currently receiving ongoing thromboprophylactic therapy with low-dose aspirin or other antiplatelet therapy * Platelet count above the lower limit of normal range * Appropriate candidate for rapid reversal of neuromuscular blockade * Sexually active females must agree to use a medically accepted method of contraception through seven days after receiving protocol-specified medication Exclusion Criteria: * Anatomical malformations that may lead to difficult intubation * Neuromuscular disorder that may affect neuromuscular blockade * History of a coagulation disorder, bleeding diathesis, systemic lupus erythematosus or antiphospholipid syndrome * History or evidence of active abnormal bleeding or blood clotting within 30 days prior to screening * Significant hepatic dysfunction * Sev…